GDF-11 – Kodiac biolabs

Our opinion on this compoundOverhyped vs evidence

34/100

Heavily contested rejuvenation factor; replication crisis and myostatin confusion undermine the core premise

Look, GDF-11 is one of the most instructive cautionary tales in recent aging biology. The 2013 Wagers and Lee parabiosis papers published in Cell generated enormous excitement: here, apparently, was a circulating youth factor that reversed age-related cardiac hypertrophy and improved skeletal muscle regeneration when old mice were connected to young blood. GDF-11 levels appeared to decline with age, and restoring them seemed to roll back the clock. The press coverage was extraordinary. The follow-up funding was substantial.

Then the replication work came in. The Glass lab at Eli Lilly and subsequent independent groups identified a core methodological problem: the immunoassays used in the original studies did not adequately distinguish GDF-11 from myostatin. These two proteins share approximately 90 percent amino acid identity in their mature domains and bind the same receptors, ActRIIA and ActRIIB, signaling through the same SMAD2/3 downstream pathway. When the assay confusion was corrected, the evidence that circulating GDF-11 actually declines with age largely evaporated. And when recombinant GDF-11 was administered at higher doses in independent labs, the effects looked less like rejuvenation and more like muscle wasting, which is exactly what you’d predict from a myostatin-homologous protein acting on the same receptor.

We’re not calling this decisively dead. A handful of groups continue to report modest pro-cardiac and pro-cognitive effects at carefully titrated, low doses, and the question of why GDF-11 and myostatin might produce divergent tissue-specific outputs despite sharing a receptor is genuinely open. Propeptide regulation and context-dependent SMAD activation are plausible explanatory angles. That question has real research value. But the original young-blood-factor story is badly damaged, theres no active clinical development pipeline, and no human translational data worth citing.

What makes GDF-11 a legitimate object of study right now is precisely its contested status. If your program touches parabiosis biology, TGF-beta superfamily receptor specificity, or aging biomarker methodology, GDF-11 is a real probe. The myostatin confusion problem has forced investigators in this space to develop much more rigorous assay standards, which is a genuine contribution to the field even if it emerged from a failed replication. Its a compound that teaches methodology as much as it illuminates biology.

What we don’t like: no human translational arrow, no consensus on whether the core rejuvenation claim survives scrutiny, and a track record of independent labs failing to replicate the headline findings. For a library focused on compelling frontier targets, GDF-11 scores as a cautionary and methodologically useful compound rather than an exciting one. Study it if your work touches parabiosis or TGF-beta superfamily receptor biology. Otherwise, there are sharper tools with cleaner evidence.

Novelty: 45
Mechanism promise: 35
In-category differentiation: 35
Evidence quality: 28
Translational signal: 18
Research bench value: 45

Rationale GDF-11 scored low across evidence and translational axes because independent replication failed to confirm the core age-decline/rejuvenation claims, the immunoassay cross-reactivity with myostatin is a fundamental methodological problem, and there is no human data or active clinical development. Bench value is modest but real for investigators working on TGF-beta superfamily biology, parabiosis methodology, or propeptide regulation in aging tissue.

TGF-beta superfamily growth differentiation factor

A growth differentiation factor in the TGF-beta superfamily originally implicated in parabiosis-mediated rejuvenation and subsequently a focus of contested replication studies in cardiac and skeletal muscle aging.

Abstract

GDF-11 (growth differentiation factor 11; bone morphogenetic protein 11, BMP-11; CAS 268544-12-9; mature peptide molecular weight approximately 12.5 kDa as a homodimer) is a member of the transforming growth factor beta (TGF-beta) superfamily, closely related to myostatin (GDF-8) with which it shares approximately 90 percent amino acid identity in the mature C-terminal domain. The compound came to prominence in 2013 when a heterochronic parabiosis study by Amy Wagers and Richard Lee at the Harvard Stem Cell Institute identified GDF-11 as a putative young-blood-borne rejuvenation factor that reversed age-related cardiac hypertrophy when administered to old mice. Subsequent studies extended the proposed rejuvenation activity to skeletal muscle and the central nervous system. The original GDF-11 papers triggered substantial follow-up research and substantial contested replication: independent groups (notably the Glass laboratory at Eli Lilly and the Wagers laboratory’s own subsequent work) reported that the original immunoassays did not adequately distinguish GDF-11 from myostatin, that circulating GDF-11 levels do not in fact decline with age, and that recombinant GDF-11 administered to old mice produces muscle wasting at high doses (consistent with the myostatin-like activity expected from the structural homology) rather than rejuvenation. The contested literature has not produced consensus; some groups continue to report modest pro-cardiac and pro-cognitive effects of GDF-11 at carefully titrated doses, while others find no effect or harmful effects. Mechanism is canonical TGF-beta superfamily signaling through ActRIIA/B receptors and downstream SMAD2/3 transcription factor activation; GDF-11 and myostatin share the same receptor and signaling pathway, distinguishing them principally through tissue-specific expression patterns and post-translational propeptide regulation. The compound is research-grade with no regulatory approval and no active clinical development. Investigators studying GDF-11 should be aware of the contested replication literature and the importance of distinguishing GDF-11 from myostatin in immunoassays.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1346Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.